AbbVie expands the production capacity of its Italian site of Campoverde of Aprilia (Latina), which will specialize in the production of drugs for the treatment of autoimmune diseases, whose introduction is expected in the coming months. A decision that the global pharmaceutical group supported with a investment of 30 million dollars.
“With the expansion of its production capacity – commented the managing director of AbbVie Italy Fabrizio Greco – of the Aprilia industrial site, AbbVie confirms its commitment in our country which is based on a long history of presence in Italy, 70 years, and generates important repercussions on the national and local economic fabric, supporting growth”.
According to the elaborations of Anac, added Greco, "the direct contribution of AbbVie and its related industries to the country's economy in 2018 was more than 520 million euros in terms of investments, salaries, direct taxes and VAT".
Established in 1963 and passed with the birth of the new biopharmaceutical company in 2013 to AbbVie, the production hub of Green field of Aprilia (Lt) covers an area of about 270.000 square meters and includes a formulation and packaging plant of finished products, two chemical plants, quality and innovation/development laboratories e services related.
The industrial site produces active principles, formulates and packages pharmaceutical products for more than 110 countries in the world. The AbbVie Italia industrial site exports more than 80% of its production. Recently the challenge was to increase production while lowering emissions into the environment: so now there is a reduction of more than 50% of the use of groundwater since 2005, zero waste sent to landfill and over 84 % earmarked for recovery.
The further strengthening of production capacity comes in addition to the various investments in innovation made in the Italian site of AbbVie for an amount of over 100 million euros in recent years.
